Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
European Research Journal ; JOUR:629-635, 8(5).
Article in English | EMBASE | ID: covidwho-2091185

ABSTRACT

Objectives: Little is known about COVID-19 and less about the B.1.1.7. There is a need for clinical information and tests to help doctors deal with the pandemic. This study aimed to investigate clinical and laboratory differences between hospitalized non-variant COVID-19 and the B.1.1.7 variant. Method(s): Data of 173 hospitalized non-variant COVID-19 and 176 B.1.1.7 variants were retrospectively investigated. D-dimer monocyte ratio (DMR) and ferritin monocyte ratio (FMR) values were calculated by dividing D-dimer and ferritin levels to monocyte count, respectively. Monocyte eosinophil ratio (MER) was obtained by dividing monocyte count by eosinophil levels. Result(s): Clinical stay, intensive care unit (ICU) stay, and severe disease rates were found to be higher in the non-variant COVID-19. Eosinophil and basophil levels remained lower, whereas ferritin, FMR, and MER were more elevated in the same group. On ROC analysis, areas under the curve (AUC) of ferritin and FMR were found as 0.7 (p = 0.001) and 0.75 (p = 0.001), respectively. Conclusion(s): The present study revealed that the B.1.1.7 variant had milder clinical manifestations, shorter clinic and ICU stay, and less severe disease rates than the non-variant COVID-19. Higher levels of ferritin, FMR, and MER may indicate the B.1.1.7 variant. Copyright © 2022 by Prusa Medical Publishing.

2.
Addicta-the Turkish Journal on Addictions ; 9(2):121-125, 2022.
Article in English | Web of Science | ID: covidwho-2072043

ABSTRACT

COVID-19 is a newly defined pandemic agent. Exposure to cigarette smoke causes increased mucosal inflammation, expression of inflammatory cytokines, impaired mucociliary clearance, and excessive mucus production. Changes in the lungs due to smoking can directly affect the outcome of the disease. In this study, we evaluated the relationship between smoking and the clinical severity of COVID-19. The charts of the patients with positive real-time polymerase chain reaction (RT-PCR) tests who received inpatient treatment in COVID-19 clinics between November 2020-April 2021 were reviewed retrospectively. Patients were divided into two groups smokers and non-smokers. We compared two groups' age, gender, laboratory parameters, mortality status, and disease severity. We included PCR proven 165 smokers and 351 non-smokers who needed hospitalization. The number of female patients was significantly lower in the smoker group (F/M: 33/132)( p < 0.001). The clinically severe patient rate was higher in the smoker group ( p = 0.005). Although the rate of mortality and patients who need ventilatory support were higher in the smoker group, the differences could not reach statistical significance. This study showed smokers had a more severe COVID-19 course than non-smokers, but the clinical outcome of severe/critical patients was not affected by the smoking status. Therefore, smokers should quit smoking urgently to be affected by the pandemic at a minimum level.

4.
Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi ; 31(3):153-160, 2021.
Article in English | Web of Science | ID: covidwho-1310170

ABSTRACT

Hematology patients are extremely vulnerable to COVID-19 infection due to the immunosuppression arising from the direct effect of the disease and the medicines administered. Our purpose is to analyze the results of the patients that both have a hematological disease and receive treatment for COVID-19 infection in our hospital. Four hundred COVID-19 positive patients that received inpatient treatment between March 12, 2020 and October 1, 2020 in our center and got a diagnosis by using real -time polymerase chain reaction (RT-PCR) test were scanned retrospectively. Eighty one patients were included in the study. Nineteen patients had a hematological disease;62 had a chronic disease but didn't have a hematological disease. We found that the group with hematological disease had a high level of ferritin (p= 0.0001). While the use of steroids in COVID-19 treatments is more frequent in the group with hematological disease (p= 0.01), the use of LMWH (low molecular weight heparin) is more frequent in the group with no hematological diseases (p= 0.02). Intensive care treatment and mechanical ventilatory support were required more for the patients with hematological disease than the others (p= 0.03. p= 0.008). While the mortality rate is 42.1% in the patients with hematological disease, it is 9.7% in the patients with chronic disease (p= 0.003). In cox regression analysis, the study found that hematological diseases (HR: 4.02, 95% CI: 1.7-1844.5, p= 0.02), cardiac diseases (HR: 2.28, 95% CI: 1.2-77.9, p= 0.03), and intensive care treatment (HR: 4.60, 95% CI: 3.1-3115.0, p= 0.009) are significant risk factors. Hematological patients infected with COVID-19 have a more severe and mortal clinical manifestation than the patients with other chronical disease.

SELECTION OF CITATIONS
SEARCH DETAIL